title: "Metronomic" chemotherapy in advanced soft tissue sarcomas.
abstract: OBJECTIVE
  Angiogenesis plays a crucial role in metastatic progression of soft tissue sarcomas (STS). Endothelial cells are the primary target of metronomic chemotherapy. We report the safety and the efficacy of metronomic chemotherapy in metastatic STS patients.
  
  
  METHODS
  The medical charts of 26 metastatic STS patients treated at Institut Bergonie (Bordeaux, France) with metronomic etoposide (100 mg/day orally for 21 consecutive days, repeated every 4 weeks) were reviewed by two independent investigators.
  
  
  RESULTS
  Median age was 49. All but three patients received prior treatment with doxorubicin and/or ifosfamide. One patient (4%) had partial response and 11 patients (42%) had stable disease for more than 24 weeks. The 6-month and the 1-year progression-free survival rates were 42% [95% CI: 23; 61] and 23% [95% CI: 7; 39], respectively. The 6-month and the 1-year overall survival rates were 69% [95% CI: 51; 87] and 31% [95% CI: 13; 49], respectively. Two patients experienced grade 4 febrile neutropenia and one of them died of sepsis.
  
  
  CONCLUSIONS
  In this series, metronomic etoposide was associated with significant clinical activity in STS. Further prospective investigations are necessary to identify those patients who are more likely to benefit from this strategy.
authors.affiliation: Department of Medical Oncology, Institut Bergonié, 229 cours de l'Argonne, 33076 Bordeaux Cedex, France. italiano@bergonie.org
authors.forename: Antoine
authors.initials: A
authors.lastname: Italiano
authors.forename: Maud
authors.initials: M
authors.lastname: Toulmonde
authors.forename: Barbara
authors.initials: B
authors.lastname: Lortal
authors.forename: Eberhard
authors.initials: E
authors.lastname: Stoeckle
authors.forename: Delphine
authors.initials: D
authors.lastname: Garbay
authors.forename: Guy
authors.initials: G
authors.lastname: Kantor
authors.forename: Michèle
authors.initials: M
authors.lastname: Kind
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Coindre
authors.forename: Binh
authors.initials: B
authors.lastname: Bui
mesh_terms: D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000009:adverse effects; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009503:Neutropenia / Q000139:chemically induced; D012509:Sarcoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D005047:Etoposide